

Isabella Nava

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9147116/publications.pdf>

Version: 2024-02-01

43
papers

1,239
citations

489802

18
h-index

406436

35
g-index

43
all docs

43
docs citations

43
times ranked

1835
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19, inflammatory response, iron homeostasis and toxicity: a prospective cohort study in the Emergency Department of Piacenza (Italy).. <i>Acta Biomedica</i> , 2022, 93, e2022057.	0.2	1
2	Epidemiological shift of glucose-6-phosphate dehydrogenase mutations in northern Italy in the last 15Åyears. <i>Annals of Hematology</i> , 2021, 100, 2683-2688.	0.8	2
3	ACTIVIN RECEPTOR LIGAND FOR THR TREATMENT OF BETA-THALASSEMIA: a SERENDIPITOUS DISCOVERY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020075.	0.5	4
4	Microcytosis in Erythropoietic Protoporphyrin. <i>Blood</i> , 2020, 136, 44-44.	0.6	0
5	Iron overload in congenital haemolytic anaemias: role of hepcidin and cytokines and predictive value of ferritin and transferrin saturation. <i>British Journal of Haematology</i> , 2019, 185, 523-531.	1.2	6
6	Inflammatory involvement into phototoxic reaction in erythropoietic protoporphyria (EPP) patients. <i>Immunologic Research</i> , 2019, 67, 382-389.	1.3	11
7	Evaluation of in Vitro Macrophage Characterization in Gaucher Type 1 (GD1) Patients. <i>Blood</i> , 2019, 134, 3592-3592.	0.6	0
8	Nonâ€transferrinâ€bound iron and oxidative stress during allogeneic hemopoietic stem cell transplantation in patients with or without iron overload. <i>American Journal of Hematology</i> , 2018, 93, E250-E252.	2.0	15
9	Circulating cellâ€free DNA and ineffective erythropoiesis in nontransfusionâ€dependent β^0 â€thalassemia. <i>American Journal of Hematology</i> , 2018, 93, E365-E368.	2.0	2
10	Anti-TNF-Mediated Modulation of Prohepcidin Improves Iron Availability in Inflammatory Bowel Disease, in an IL-6-Mediated Fashion. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017, 2017, 1-12.	0.8	25
11	Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: Kinetics of its appearance and potential predictive role in infectious complications. <i>Leukemia Research</i> , 2015, 39, 88-91.	0.4	18
12	The role of TMPRSS6 polymorphisms in iron deficiency anemia partially responsive to oral iron treatment. <i>American Journal of Hematology</i> , 2015, 90, 306-309.	2.0	32
13	Does TMPRSS6 RS855791 Polymorphism Contribute to Iron Deficiency in Treated Celiac Disease?. <i>American Journal of Gastroenterology</i> , 2015, 110, 200-202.	0.2	23
14	Role of Non-Transferrin-Bound Iron in the pathogenesis of cardiotoxicity in patients with ST-elevation myocardial infarction assessed by Cardiac Magnetic Resonance Imaging. <i>International Journal of Cardiology</i> , 2015, 199, 326-332.	0.8	16
15	Growth Differentiation Factor 15 expression and regulation during erythroid differentiation in non-transfusion dependent thalassemia. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 54, 26-28.	0.6	10
16	Combination of deferasirox and deferoxamine in clinical practice: An alternative scheme of chelation in thalassemia major patients. <i>Blood Cells, Molecules, and Diseases</i> , 2014, 53, 164-167.	0.6	39
17	An Intriguing Case of Anaemia and Splenomegaly. <i>European Journal of Case Reports in Internal Medicine</i> , 2014, 1, .	0.2	1
18	Very high frequency of <sc><i>TMPRSS6</i></sc> gene variations in iron deficiency anaemia of patients with polyendocrine autoimmune syndromes: more than a casual association?. <i>British Journal of Haematology</i> , 2013, 161, 147-150.	1.2	3

#	ARTICLE	IF	CITATIONS
19	Analysis Of TMPRSS6 Polymorphisms In Patients With Iron Deficiency Anemia Partially Responsive To Oral Iron Treatment. <i>Blood</i> , 2013, 122, 3438-3438.	0.6	1
20	Fetal hemoglobin levels and morbidity in untransfused patients with β^2 -thalassemia intermedia. <i>Blood</i> , 2012, 119, 364-367.	0.6	85
21	Erythropoietin in Friedreich ataxia: No effect on frataxin in a randomized controlled trial. <i>Movement Disorders</i> , 2012, 27, 446-449.	2.2	57
22	Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with β^2 thalassemia intermedia. <i>Blood Cells, Molecules, and Diseases</i> , 2011, 47, 232-234.	0.6	55
23	Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes. <i>PLoS ONE</i> , 2011, 6, e23109.	1.1	95
24	Nontransferrin-bound iron in transfused patients with sickle cell disease. <i>International Journal of Laboratory Hematology</i> , 2011, 33, 133-137.	0.7	11
25	Hepcidin mutation in a β^2 -thalassemia major patient with persistent severe iron overload despite chelation therapy. <i>Internal and Emergency Medicine</i> , 2010, 5, 83-85.	1.0	3
26	Genetic variability of <i>TMPRSS6</i> and its association with iron deficiency anaemia. <i>British Journal of Haematology</i> , 2010, 151, 281-284.	1.2	33
27	High nontransferrin bound iron levels and heart disease in thalassemia major. <i>American Journal of Hematology</i> , 2009, 84, 29-33.	2.0	128
28	Mutation analysis of hepcidin and ferroportin genes in Italian prospective blood donors with iron overload. <i>American Journal of Hematology</i> , 2009, 84, 592-593.	2.0	7
29	Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. <i>British Journal of Haematology</i> , 2009, 146, 569-572.	1.2	66
30	Iron Burden and Liver Fibrosis Decrease During a Long-Term Phlebotomy Program and Iron Chelating Treatment After Bone Marrow Transplantation. <i>Hemoglobin</i> , 2006, 30, 131-137.	0.4	12
31	Changes in erythropoiesis, iron metabolism and oxidative stress after half-marathon. <i>Internal and Emergency Medicine</i> , 2006, 1, 30-34.	1.0	18
32	Identification of a New Mutation in the 5' UTR of Hepcidin Gene in beta-Thalassemia Major (TM) Patients.. <i>Blood</i> , 2006, 108, 3811-3811.	0.6	0
33	Erythrocyte ferritin concentration: analytical performance of the immunoenzymatic IMx-Ferritin (Abbott) assay. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 449-53.	1.4	9
34	Design of a trial comparing sirolimus plus mycophenolate mofetil versus sirolimus plus cyclosporine. <i>Transplantation Proceedings</i> , 2003, 35, S62-S63.	0.3	1
35	Red blood cell antioxidant and iron status in alcoholic and nonalcoholic cirrhosis. <i>European Journal of Clinical Investigation</i> , 2002, 32, 21-27.	1.7	16
36	Oxidative status and malondialdehyde in β^2 -thalassaemia patients. <i>European Journal of Clinical Investigation</i> , 2002, 32, 55-60.	1.7	115

#	ARTICLE	IF	CITATIONS
37	Membrane-bound iron contributes to oxidative damage of $\hat{\text{I}}^2$ -thalassaemia intermedia erythrocytes. British Journal of Haematology, 2001, 112, 48-50.	1.2	68
38	Non-Transferrin-Bound Iron in Alcohol Abusers. Alcoholism: Clinical and Experimental Research, 2001, 25, 1494-1499.	1.4	16
39	Non-transferrin-bound iron, iron-related oxidative stress and lipid peroxidation in $\hat{\text{I}}^2$ -thalassemia intermedia. Transfusion Science, 2000, 23, 245-246.	0.6	22
40	Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?. The Hematology Journal, 2000, 1, 153-158.	2.0	62
41	Metabolic indicators of oxidative stress correlate with haemichrome attachment to membrane, band 3 aggregation and erythrophagocytosis in $\hat{\text{I}}^2$ -thalassaemia intermedia. British Journal of Haematology, 1999, 104, 504-512.	1.2	76
42	Carbohydrate-deficient transferrin, a sensitive marker of chronic alcohol abuse, is highly influenced by body iron. Hepatology, 1999, 29, 658-663.	3.6	74
43	Erythrocyte membrane alterations in thalassemia intermedia. Clinical Hemorheology and Microcirculation, 1996, 16, 789-797.	0.9	1